FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897874044> ?p ?o ?g. }

• W2897874044 abstract "Purpose of the study. A comparative evaluation of the effectiveness of different therapeutic strategies in patients with polycythemia vera (PV) and essential thrombocythemia (ET). Materials and methods. Patients with PV or ET, diagnosed according to the criteria WHO 2016 were included in the study. The primary endpoint - 6 months of therapy (clinical-hematological and molecular responses). The secondary endpoint - 12 months of therapy (clinico-hematologic, molecular, histological responses). Sixty three patients were included in the analysis: the first group consisted of 33 patients who received the therapy with ce-pegiterferone alpha-2b (ce-pegalpha-INF-α-2b), 10 of them received previous treatment; the second group - 23 patients btained hydroxycarbamide; the third group - 7 patients were treated with recombinant interferon alpha therapy (rINFα). In comparison groups, differences in age were revealed: patients receiving hydroxycarbamide therapy were older. Phlebotomy occurred in 36% of patients in the first group, 9% in the second group, and 14% in the third group. Results. By the 6th month of therapy, 43% of the patients receiving the ce-pegalpha-INF-α-2b had complete clinical-hematologic response, 36% had partial clinical-hematologic remission and stabilization of the disease was established in 21% cases. No disease progression occured. By the 12th month of therapy, statistically significant differences in terms of efficacy between the different therapeutic groups (p = 0.2462, Fisher's exact test). In all three groups, the allelic load of JAK2V617F decreased: from 50 to 19%, from 22.3 to 15.8%, from 50 to 7.19%, respectively. The lower the allele load positively correlated with better response to therapy, which was observed in all analyzed groups. Hematologic adverse events (AEs) were more frequently observed in patients receiving ce-pegalpha-INF-α-2b therapy. Local reactions developed on 3-7 days of therapy as a hyperemic macula at the injection site. Both these reactions and hair loss did not influence on patient’s condition. In the second group (patients with hydroxycarbamide therapy) there were changes in the skin and mucous membranes: dry skin, stomatitis, and in older patients new keratomas appeared. The flu-like syndrome was the most common adverse event associated with the therapy of ce-pegalpha-INF-α-2b, which fully relived during the first month of therapy. There was only one case with the flu-like syndrome we observed at the 11th month of therapy. As a rule, the biochemical blood test changes did not influence on patient’s condition, were mostly associated with dietary violations, had a tendency to self-resolution and did not require medical interventions. Serious AEs were reported in one case - pulmonary embolism in a patient treated with rINFα. The reasons for the therapy discontinue in group 1: toxic hepatitis, intolerance, by the request of the patient, inadequate efficacy of therapy; in group 2: skin toxicity, in group 3: thromboses. The conclusion. Treatment of ce-pegalpha-INF-α-2b in patients with PV and ET is highly effective - the most patients pbtained clinical and hematological responses. There were no statistically significant differences in these parameters in comparison with hydroxycarbamide and rINFα. The use of the ce-pegalpha-INF-α-2b had an acceptable safety profile. The estimated therapeutic dose should be calculated according to body weight. To reduce the frequency of hematologic AE, titration of the drug dose is required." @default.
• W2897874044 created "2018-10-26" @default.
• W2897874044 creator A5030894453 @default.
• W2897874044 creator A5038816801 @default.
• W2897874044 creator A5041606049 @default.
• W2897874044 creator A5046495435 @default.
• W2897874044 creator A5049170583 @default.
• W2897874044 creator A5059723473 @default.
• W2897874044 creator A5068078725 @default.
• W2897874044 creator A5069763928 @default.
• W2897874044 creator A5070261411 @default.
• W2897874044 creator A5078634760 @default.
• W2897874044 creator A5080278240 @default.
• W2897874044 creator A5085667359 @default.
• W2897874044 creator A5086935204 @default.
• W2897874044 date "2018-07-15" @default.
• W2897874044 modified "2023-09-23" @default.
• W2897874044 title "Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases" @default.
• W2897874044 cites W2010298229 @default.
• W2897874044 cites W2011059916 @default.
• W2897874044 cites W2024706907 @default.
• W2897874044 cites W2083179131 @default.
• W2897874044 cites W2094456737 @default.
• W2897874044 cites W2094487700 @default.
• W2897874044 cites W2097692898 @default.
• W2897874044 cites W2185322154 @default.
• W2897874044 cites W2767250221 @default.
• W2897874044 doi "https://doi.org/10.26442/terarkh201890723-29" @default.
• W2897874044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30701919" @default.
• W2897874044 hasPublicationYear "2018" @default.
• W2897874044 type Work @default.
• W2897874044 sameAs 2897874044 @default.
• W2897874044 citedByCount "4" @default.
• W2897874044 countsByYear W28978740442019 @default.
• W2897874044 countsByYear W28978740442020 @default.
• W2897874044 countsByYear W28978740442022 @default.
• W2897874044 crossrefType "journal-article" @default.
• W2897874044 hasAuthorship W2897874044A5030894453 @default.
• W2897874044 hasAuthorship W2897874044A5038816801 @default.
• W2897874044 hasAuthorship W2897874044A5041606049 @default.
• W2897874044 hasAuthorship W2897874044A5046495435 @default.
• W2897874044 hasAuthorship W2897874044A5049170583 @default.
• W2897874044 hasAuthorship W2897874044A5059723473 @default.
• W2897874044 hasAuthorship W2897874044A5068078725 @default.
• W2897874044 hasAuthorship W2897874044A5069763928 @default.
• W2897874044 hasAuthorship W2897874044A5070261411 @default.
• W2897874044 hasAuthorship W2897874044A5078634760 @default.
• W2897874044 hasAuthorship W2897874044A5080278240 @default.
• W2897874044 hasAuthorship W2897874044A5085667359 @default.
• W2897874044 hasAuthorship W2897874044A5086935204 @default.
• W2897874044 hasBestOaLocation W28978740441 @default.
• W2897874044 hasConcept C126322002 @default.
• W2897874044 hasConcept C141071460 @default.
• W2897874044 hasConcept C203014093 @default.
• W2897874044 hasConcept C203092338 @default.
• W2897874044 hasConcept C2776178377 @default.
• W2897874044 hasConcept C2777357209 @default.
• W2897874044 hasConcept C2778837598 @default.
• W2897874044 hasConcept C2779134260 @default.
• W2897874044 hasConcept C2779316324 @default.
• W2897874044 hasConcept C2780829020 @default.
• W2897874044 hasConcept C2781057849 @default.
• W2897874044 hasConcept C2909179924 @default.
• W2897874044 hasConcept C535046627 @default.
• W2897874044 hasConcept C71924100 @default.
• W2897874044 hasConcept C90924648 @default.
• W2897874044 hasConceptScore W2897874044C126322002 @default.
• W2897874044 hasConceptScore W2897874044C141071460 @default.
• W2897874044 hasConceptScore W2897874044C203014093 @default.
• W2897874044 hasConceptScore W2897874044C203092338 @default.
• W2897874044 hasConceptScore W2897874044C2776178377 @default.
• W2897874044 hasConceptScore W2897874044C2777357209 @default.
• W2897874044 hasConceptScore W2897874044C2778837598 @default.
• W2897874044 hasConceptScore W2897874044C2779134260 @default.
• W2897874044 hasConceptScore W2897874044C2779316324 @default.
• W2897874044 hasConceptScore W2897874044C2780829020 @default.
• W2897874044 hasConceptScore W2897874044C2781057849 @default.
• W2897874044 hasConceptScore W2897874044C2909179924 @default.
• W2897874044 hasConceptScore W2897874044C535046627 @default.
• W2897874044 hasConceptScore W2897874044C71924100 @default.
• W2897874044 hasConceptScore W2897874044C90924648 @default.
• W2897874044 hasLocation W28978740441 @default.
• W2897874044 hasLocation W28978740442 @default.
• W2897874044 hasOpenAccess W2897874044 @default.
• W2897874044 hasPrimaryLocation W28978740441 @default.
• W2897874044 hasRelatedWork W2035529203 @default.
• W2897874044 hasRelatedWork W2046614399 @default.
• W2897874044 hasRelatedWork W2064180006 @default.
• W2897874044 hasRelatedWork W2080230477 @default.
• W2897874044 hasRelatedWork W2088272024 @default.
• W2897874044 hasRelatedWork W2324926716 @default.
• W2897874044 hasRelatedWork W2571034276 @default.
• W2897874044 hasRelatedWork W2605734333 @default.
• W2897874044 hasRelatedWork W2897874044 @default.
• W2897874044 hasRelatedWork W3217589894 @default.
• W2897874044 isParatext "false" @default.
• W2897874044 isRetracted "false" @default.
• W2897874044 magId "2897874044" @default.
• W2897874044 workType "article" @default.